BPC-157 is a synthetic peptide, a lab-made copy of a fragment of a protein found in stomach fluid, sold online for healing tendons, ligaments, and the gut. Nearly all of the evidence behind those uses comes from studies in rats and other animals and from cells in a dish. In those models it speeds the healing of cut tendon, ligament, and muscle and of gut lesions and fistulas, and it promotes the growth of new blood vessels. No adequate human trial has tested whether it does any of this in people.
It is not an approved medicine anywhere. It is sold as a research chemical outside pharmaceutical controls, so what is in a given vial is often unverified, its long-term safety in humans is unknown, and it is banned in competitive sport. This page covers what it is, what the animal and cell studies found, and why no human trial has yet tested it in people. It gives no dosing.
Findings & Outcomes
What It Is
BPC-157 stands for Body Protection Compound 157. It is a chain of fifteen amino acids, a pentadecapeptide, and its sequence was taken from a larger protective protein identified in human gastric juice. It is made in a laboratory, and it is stable in stomach acid, which is unusual for a peptide. It is a synthesized partial sequence studied since the 1990s, not the natural protein itself, and it has never been approved as a medicine in any country.
It is sold online, as a capsule, an oral liquid, or a powder for injection, for a long list of uses: healing tendons, ligaments, and muscle after injury, easing joint and tendon pain, healing the gut lining, and recovering faster from surgery. Almost all of the support for those uses comes from animal experiments and cell studies. It reaches buyers as a research chemical, a product sold for laboratory use with no check on its identity, dose, purity, or sterility, and with no regulator standing behind what the label says.
Anatomy
1The peptide
BPC-157 is a short synthetic peptide of fifteen amino acids. Its sequence copies a stretch of a larger protein found in human gastric juice, the fluid the stomach uses to protect and repair its own lining. The synthesized fragment is what is studied and sold; the full natural protein is a separate thing. Its resistance to stomach acid is the property most often cited in favor of an oral form.
2The forms sold
It is sold as oral capsules and liquids and as a powder that buyers reconstitute and inject under the skin or near an injured tendon or joint. Most of the marketing centers on the injectable form. None of these products is a licensed drug, and their contents are not verified by any authority. Injecting a reconstituted research powder adds the separate risks of an unsterile product.
3How it is studied
The research is almost entirely preclinical: rats and mice with surgically created injuries, and cells grown in culture. In those settings BPC-157 has been given by injection and in drinking water. The doses used in animals do not translate into a human dose, and no adequate human trial has established a dose that is safe and effective in people.
What It Does
The findings come almost entirely from animals and cells, and each one below is labeled with the kind of study behind it. In rats, BPC-157 speeds the healing of a surgically cut Achilles tendon and improves the recovery of movement afterward. It improves the healing of a cut knee ligament and of crushed muscle in the same kind of rat model. In rat models of gut injury it heals lesions and closes fistulas, abnormal channels between the bowel and nearby organs. In cell and animal studies it promotes angiogenesis, the growth of new blood vessels, which is part of how any of these tissues repair.
None of this has been shown in people. There is no adequate human randomized trial of BPC-157 for any of these uses. The animal healing signal is consistent across many studies from a small number of laboratories, and it is the reason the peptide is sold, but a result in a rat with a surgical wound is a starting point for human research, not a substitute for it. What a compound does in people can differ from what it does in animals in both direction and size, which is the whole reason human trials exist.
Everything BPC-157 is sold to do rests on animal and cell studies. No adequate human trial has tested whether it heals anything in people, and it is sold as an unregulated product whose contents are often unverified.
The Research & Studies
Everything here is based on the research we have collected and checked, sorted into groups and ordered with the strongest evidence first. Click any claim to open the studies behind it.
How it works
BPC-157 is a synthetic pentadecapeptide derived from a protein in gastric juice, stable in stomach acid
BPC-157 is a lab-made copy of a small piece of a protein found in stomach fluid. It survives stomach acid, which is unusual for a peptide. Reviews describe what it does in animals and cells; it is not the natural protein and it is not an approved medicine.
BPC-157 (Body Protection Compound 157) is a stable gastric pentadecapeptide, a synthesized partial sequence of a protein found in human gastric juice. Review articles characterize it as a cytoprotective mediator with effects on the gastrointestinal tract and vascular system observed across many preclinical experiments. These are review summaries of animal and cell work, not human outcome data.
Who this may not transfer to:This is a description of the compound and its preclinical characterization, not a measurement in people, so it conveys what BPC-157 is rather than an effect size that transfers to any group.
The study · 1
Sikiric et al., Novel Cytoprotective Mediator, Stable Gastric Pentadecapeptide BPC 157. Vascular Recruitment and Gastrointestinal Tract Healing · Curr Pharm Des 2018;24(18):1990-2001
BPC-157 promotes new blood vessel growth through VEGFR2 in cell and animal studies
In cells grown in a dish and in animals, BPC-157 helped grow new blood vessels by switching on a receptor called VEGFR2. New blood supply is part of how any tissue repairs, which is the proposed reason it might speed healing. This is a lab observation, not a benefit shown in a person.
Hsieh and colleagues (2017) reported that the pro-angiogenic activity of BPC-157 was associated with activation and up-regulation of VEGFR2 (VEGF receptor 2) in vascular endothelial cells, with supporting effects on endothelial tube formation and vessel growth. This is a cell-level and animal mechanism study; it describes a plausible route to tissue repair but does not measure healing in humans.
Who this may not transfer to:Measured in cultured endothelial cells and animals. The angiogenic mechanism is a laboratory finding, and whether it produces any benefit in a person was not tested.
The study · 1
Hsieh et al., Therapeutic potential of pro-angiogenic BPC157 is associated with VEGFR2 activation and up-regulation · J Mol Med (Berl) 2017;95(3):323-333
BPC-157 sped healing of a surgically cut Achilles tendon in rats
In rats with a surgically cut Achilles tendon, BPC-157 helped the tendon heal and the animals recover movement sooner. This is an animal study; it has not been shown to heal tendons in people.
Krivic and colleagues (2008) transected the Achilles tendon-to-bone unit in rats and found that BPC-157 improved early functional recovery, in a model also used to compare it against the corticosteroid methylprednisolone. Related rat work by Chang and colleagues (2011) reported that BPC-157 promoted tendon healing with increased tendon fibroblast outgrowth, survival, and migration. These are consistent animal and cell findings; no human trial has tested tendon healing.
Who this may not transfer to:Measured in a rat tendon-transection model. The healing signal is an animal finding, and whether it occurs in a human tendon was not tested.
The study · 1
Krivic et al., Modulation of early functional recovery of Achilles tendon to bone unit after transection by BPC 157 and methylprednisolone · Inflamm Res 2008;57(5):205-210
BPC-157 improved ligament healing in rats
In rats with a cut knee ligament, BPC-157 improved healing. This is an animal study, and the same effect has not been shown in people.
Cerovecki and colleagues (2010) transected the medial collateral ligament in rats and found that BPC-157 (studied under the code PL 14736) improved ligament healing on functional, biomechanical, macroscopic, and microscopic measures. This is a controlled animal model; there is no human trial of BPC-157 for ligament injury.
Who this may not transfer to:Measured in a rat ligament-transection model. The healing effect is an animal finding, and whether it occurs in a human ligament was not tested.
The study · 1
Cerovecki et al., Pentadecapeptide BPC 157 (PL 14736) improves ligament healing in the rat · J Orthop Res 2010;28(9):1155-1161
BPC-157 sped recovery of crushed muscle in rats
In rats with crushed muscle, BPC-157 helped the muscle heal and regain function. This is an animal study, and it has not been shown to work the same way in people.
Novinscak and colleagues (2008) produced a crush injury of the gastrocnemius muscle complex in rats and found that BPC-157 improved healing and functional recovery. Related rat work by Staresinic and colleagues (2006) reported effective therapy of a transected quadriceps muscle. These are consistent animal findings; no human trial has tested muscle healing.
Who this may not transfer to:Measured in a rat muscle-crush model. The recovery signal is an animal finding, and whether it occurs in human muscle was not tested.
The study · 1
Novinscak et al., Gastric pentadecapeptide BPC 157 as an effective therapy for muscle crush injury in the rat · Surg Today 2008;38(8):716-725
BPC-157 raised growth hormone receptor expression in cultured tendon cells
In tendon cells grown in a dish, BPC-157 raised the amount of the growth hormone receptor and made the cells multiply more. This is one proposed way it might speed tendon healing. It is a cell-level lab finding, not a benefit shown in a person.
Chang and colleagues (2014) found that BPC-157 enhanced growth hormone receptor expression in cultured tendon fibroblasts and increased cell proliferation in a dose-dependent way, which the authors proposed could sensitize tendon cells to growth hormone and support tendon healing. This is an in-vitro mechanism; it does not measure tendon healing in an animal or a person.
Who this may not transfer to:Measured in cultured tendon cells. The receptor and proliferation changes are a laboratory mechanism, and whether they translate into healing in a person was not tested.
The study · 1
Chang et al., Pentadecapeptide BPC 157 enhances the growth hormone receptor expression in tendon fibroblasts · Molecules 2014;19(11):19066-19077
BPC-157 relaxed isolated human artery tissue through the nitric oxide pathway
In pieces of human artery studied in a lab dish, BPC-157 made the vessel relax through the nitric oxide pathway, the system that widens blood vessels. This is isolated-tissue evidence for how it acts on blood vessels, not a measured effect in a living person.
Yildirim and colleagues (2026) tested BPC-157 on isolated segments of human internal mammary artery and found an endothelium-dependent vasorelaxant effect mediated by nitric oxide. This adds human-tissue support for the peptide's interaction with the nitric oxide system, a pathway repeatedly implicated in its animal effects. It is an ex-vivo tissue study, not a measurement of any outcome in a living person.
Who this may not transfer to:Measured in isolated human artery tissue in the laboratory. The vasorelaxant mechanism describes how BPC-157 acts on vessels and is not an outcome measured in a living person.
The study · 1
Yildirim et al., Endothelium-Dependent Nitric Oxide-Mediated Vasorelaxant Effects of BPC 157 in Human Internal Mammary Artery · J Clin Med 2026;15(9)
Digestion
BPC-157 healed gut lesions and closed a fistula in rats
In rats with an abnormal channel between the bowel and bladder, BPC-157 helped the channel close and the tissue heal. It has healed gut injuries in several rat models. None of this has been tested in people.
Grgic and colleagues (2016) found that BPC-157 healed colovesical fistula in rats, improving closure and tissue healing. This sits among many rat studies of BPC-157 in gastrointestinal injury and inflammatory bowel models reviewed by Sikiric and colleagues. The gut-healing evidence is consistent across animal models from a small number of laboratories; there is no adequate human trial for inflammatory bowel disease or any gastrointestinal condition.
Who this may not transfer to:Measured in a rat fistula model. The gut-healing signal is an animal finding, and whether it occurs in the human gut was not tested.
The study · 1
Grgic et al., Stable gastric pentadecapeptide BPC 157 heals rat colovesical fistula · Eur J Pharmacol 2016;780:1-7
How It Works
The mechanism most often described is angiogenesis. In cultured blood-vessel cells and in animals, BPC-157 promotes the growth of new blood vessels, and this effect is linked to activation of VEGFR2, a receptor that drives blood-vessel formation. New blood supply is part of how a tendon, ligament, or gut wall repairs, so a compound that promotes it has a plausible route to speeding repair. This is a mechanism observed in the laboratory, not a demonstrated benefit in a person.
Two other mechanisms appear in the research. BPC-157 interacts with the nitric oxide system, the signaling pathway that relaxes blood vessels and regulates blood flow, and in isolated human artery tissue it produced an endothelium-dependent relaxation of the vessel. In cultured tendon cells it raised the expression of the growth hormone receptor and increased cell growth, which is one proposed route to faster tendon repair. Both are cell-level or isolated-tissue observations. They describe how the peptide might act; they do not show that it repairs tissue in a living person.
The same angiogenesis that could help a wound heal is a reason for caution. Growing new blood vessels is also part of how tumors expand, and no long human study has looked at whether promoting angiogenesis with this peptide carries a cancer risk. That question is unanswered, and it is one of several reasons the human safety picture is blank rather than reassuring.
How To Think About It
How To Think About It
There is no protocol here, because this is education, not a recommendation to take anything. The plainest routes to the healing people want from BPC-157 are the ones with human evidence behind them, and a real injury is a reason to get a diagnosis rather than to self-treat.
Tendons and muscle repair with graded loading and time, and human trials support progressive rehabilitation, adequate protein, and sleep for recovery. These are the best-evidenced levers for the healing goal that draws people to BPC-157, and they carry none of the unknowns of an unregulated injectable.
Persistent tendon, joint, or gut symptoms deserve a diagnosis. A torn tendon, a structural gut problem, or pain that is not improving can need a specific treatment, and self-treating with a research chemical can delay finding out what is actually wrong. A clinician or physical therapist is the step here.
BPC-157 is sold with confident healing claims that the human evidence does not support. The animal results are real, and they are a reason for interest and for further research; they are not a reason to inject an experimental substance. Treat the online claims as marketing ahead of the evidence.
A product sold as a research chemical is not a medicine. No authority checks its identity, dose, purity, or sterility, and testing of gray-market peptides has found wrong doses, missing active ingredient, and contamination. What is in a given vial is uncertain, and that uncertainty is part of the risk.
Go Deeper
- Peptides: the wider category BPC-157 belongs to, and how to keep the few approved peptide drugs apart from the many unregulated ones.
- TB-500: the sibling healing peptide sold the same way, with the same shape of evidence, rodent research and no completed human trial.
- Growth hormone secretagogues: the other frontier peptides sold for muscle and recovery, where the same rule about moving a marker versus changing an outcome applies.
- Resistance training: the loading that repairs and strengthens tendon and muscle, with human evidence behind it.
- Protein and muscle: what to eat to give repair its building blocks, the food-first side of recovery.
The Chinese Medicine View
BPC-157 is a product of modern peptide chemistry, synthesized in the last few decades, so there is no classical Chinese entry for it. No historical text assigns it a channel, a temperature, or a flavor, and no traditional formula contains it. Read the tradition here as a lens, not as evidence for the peptide. It supplies no classical claim, because none exists, and nothing here suggests any herb or formula reproduces what this compound does in a rat.
The tradition does reason about the same territory of healing. Chinese medicine holds that the Spleen governs the muscles and flesh, the Liver governs the sinews, meaning the tendons and ligaments, and the Kidney governs the bones, and it treats the repair of an injury as the work of Qi and Blood knitting tissue back together. A slow-healing wound is often read as a deficiency of Qi and Blood or as stagnation blocking their flow, and the classical approach is to support the person's capacity to heal with herbs, food, and rest rather than to add a single isolated agent.
Here the tradition adds a caution rather than an endorsement. Building the body up is held to suit a true deficiency in a person who can absorb what is given, and forcing a system is understood to deplete it. This connects a modern compound to a framework the tradition has long used; it is not a claim that Chinese medicine anticipated, endorses, or explains BPC-157. The evidence for the peptide stands or falls on the studies, which remain in animals.
Cautions
Everything to be aware of is here, in one place. This practice suits most healthy people; a few situations call for real care.
The BPC-157 evidence base is preclinical, with no adequate human trial of efficacy or safety
Seiwerth and colleagues (2021) reviewed the wound-healing evidence for BPC-157 and describe a large preclinical literature in animals and cells, without an adequate human randomized trial establishing efficacy or long-term safety. The consistency of the animal signal, across many studies from a small number of laboratories, is the reason for continued interest, but the human case remains untested.Seiwerth et al., Stable Gastric Pentadecapeptide BPC 157 and Wound Healing
Not an approved medicine, and sold as a research chemical
BPC-157 is not approved as a drug in any country. It is sold as a research chemical, outside pharmaceutical controls, so no authority verifies its identity, dose, purity, or sterility. Testing of gray-market peptides has found wrong doses, missing active ingredient, and contamination, and the injectable form adds the risks of self-injecting a product that was never made to be sterile. In the United States the FDA has flagged BPC-157 as lacking the safety data needed for pharmacy compounding.
Human safety is unknown
There is no adequate human trial of BPC-157, which means its safety in people, including its long-term safety, has not been established. The absence of reported harm is not the same as evidence of safety; it reflects that almost no one has been studied. Anyone considering it is acting on animal data and personal reports, without the human safety record that an approved medicine carries.
The angiogenesis and cancer question is open
The same growth of new blood vessels that is proposed to help wounds heal is also part of how tumors grow. No long human study has looked at whether promoting angiogenesis with this peptide affects cancer risk. This is an unanswered concern, not a proven harm, and it is a particular reason for caution in anyone with a personal or family history of cancer.
Banned in competitive sport
BPC-157 is prohibited by the World Anti-Doping Agency, which lists it among non-approved substances banned at all times. Any athlete subject to drug testing who uses it risks a sanction, and this holds whether it is taken by mouth or injected.
No data in pregnancy, breastfeeding, or children
BPC-157 has not been studied in pregnancy, breastfeeding, or children, so there is no basis for judging it safe in any of them. With no human data at all, avoiding it in these groups is the only defensible position.
A real injury needs a diagnosis, not a self-designed experiment
Persistent or severe pain, a tendon or muscle that is not recovering, or gut symptoms can signal a problem that needs a specific treatment. Self-treating with an experimental substance can delay a diagnosis. A clinician or physical therapist who can identify what is wrong is the step here, not a vial from a website.
Start slow, be smart, read the research, and consult a professional if you have any concerns. This is here to inform your choice, not make it for you.
Common Questions
Does BPC-157 actually heal tendons and injuries?
In rats, it speeds the healing of surgically cut tendon, ligament, and muscle and improves the recovery of movement, and those animal results are consistent across many studies. In people, this has not been shown. There is no adequate human trial of BPC-157 for tendon, ligament, muscle, or joint injury, so the healing claims made for it online rest on animal data, not on evidence that it works in a person. A rat result is a reason for research, not proof of a human benefit.
Is BPC-157 safe?
Its safety in people is unknown, because there is almost no human data. No adequate human trial has measured its effects or its risks, so its short-term and long-term safety in humans have not been established. On top of that, it is sold as an unregulated research chemical, so what is in a given vial is often unverified, and the injectable form carries the added risks of an unsterile product. The angiogenesis it promotes also raises an unanswered question about cancer risk.
Is BPC-157 legal or approved?
It is not approved as a medicine in any country. It is sold as a research chemical, a product marketed for laboratory use rather than for human treatment, which is how it reaches buyers without going through drug approval. In the United States the FDA has flagged it as lacking the safety data needed for pharmacy compounding. It is also banned in competitive sport by the World Anti-Doping Agency.
Is the oral or the injectable form better?
Neither has been shown to work in people, so there is no evidence-based answer, and this page gives no dosing. BPC-157 is unusually stable in stomach acid, which is the argument made for an oral form, and animal studies have used both oral and injected routes. The injectable form is the one most marketed, and it carries the extra risks of injecting an unsterile, unverified product. Without a human trial, any choice between the two rests on animal data and marketing.
Explore Related
Other pages this one connects to, by the evidence they share, the outcomes they touch, and the ground they cover.
All 9 sources on this page independently checked and cross-referenced.
Thomas Dehli, Founder & Editor, Sacred Lotus
Sacred Lotus has published Chinese medicine reference material since 2001. Integrative pages are held to the same standard as the herb and formula library: cite the source, grade the claim at its real strength, and say where the research has not looked. This page is educational and it is not medical advice. Last reviewed and updated August 10, 2026.
Evidence strength
How confidently the research supports a claim. Strength describes the evidence, not our endorsement.